GlassScriptPhysician profile
Jeffrey Cabot Clevenger
NPI 1801876909
$4,166.56
in general payments reported to CMS, 2019-2025
24 companies · $427 in 2025
The $427 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $284 · 2021: $929 · 2022: $381 · 2023: $168 · 2024: $1,779 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,596 · Travel and Lodging: $777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,596.08 |
| Travel and Lodging | $777.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,301.81 | 2021-2024 | Linq II |
| Boston Scientific Corporation | $904.78 | 2019-2025 | Watchman Flx, Bodyguardian, Watchman Access System |
| Janssen Pharmaceuticals, INC | $617.45 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $150.92 | 2021-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.91 | 2020-2021 | |
| Cvrx, INC. | $127.14 | 2022 | |
| Amarin Pharma, INC. | $123.06 | 2021 | |
| Merck Sharp & Dohme LLC | $110.83 | 2021-2022 | |
| Pfizer INC. | $109.38 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $97.23 | 2019-2022 | |
| Amgen INC. | $96.25 | 2019-2025 | Repatha |
| Alnylam Pharmaceuticals INC. | $85.39 | 2024-2025 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $84.73 | 2020-2022 | |
| Mylan Specialty L.P. | $34.02 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.20 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $25.15 | 2024 | Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $19.63 | 2021 | |
| Esperion Therapeutics, INC. | $18.76 | 2025 | Nexletol |
| Scpharmaceuticals INC. | $18.55 | 2024 | |
| Abbott Laboratories | $16.83 | 2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Teva Pharmaceuticals USA, INC. | $13.41 | 2021 | |
| Irhythm Technologies, INC. | $13.34 | 2019 | |
| Pulmonx Corporation | $12.00 | 2021 | |
| Medtronic Vascular, INC. | $11.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Clevenger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.